Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Fineline Cube Apr 27, 2026
Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Fineline Cube Apr 27, 2026
Company Deals

Mindray Partners with Vazyme Biotech to Develop Automated Infection Screening Solutions

Fineline Cube May 30, 2023

China-based medical device company Mindray (SHE: 300760) has entered into a partnership with fellow Chinese...

Company Drug

Hisun Pharmaceutical’s SHP2 Inhibitor HS336 Gets NMPA Clinical Trial Approval

Fineline Cube May 30, 2023

Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a China-based pharmaceutical company, has announced that it...

Policy / Regulatory

Hainan Boao Lecheng Introduces 319 Overseas Drugs and Devices, Reports Significant Growth

Fineline Cube May 30, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has introduced 319 clinically urgently needed...

Company

Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology

Fineline Cube May 29, 2023

US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district...

Drug Policy / Regulatory

Hubei Leads National Volume-Based Procurement of Patented Traditional Chinese Medicines

Fineline Cube May 29, 2023

The Healthcare Security Administration (HSA) bureau of Hubei province has released a notification outlining plans...

Company Drug

Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals

Fineline Cube May 29, 2023

China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib...

Company Drug

Ascentage Pharma’s Olverembatinib Earns Breakthrough Designation for SDH-Deficient GIST

Fineline Cube May 29, 2023

The China’s Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) to olverembatinib,...

Company Drug

Abbisko Therapeutics Reports Positive Phase Ib Results for ABSK021 at ASCO

Fineline Cube May 29, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) is poised to announce positive results from...

Company Drug

Shanghai Yizhong’s Paclitaxel Micelles Data to be Presented at ASCO Annual Meeting

Fineline Cube May 29, 2023

Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091), a China-based pharmaceutical company, has announced that clinical...

Legal / IP

SAMR Imposes Penalties on Grand Pharma and WuHan Huihai for Monopoly Agreements

Fineline Cube May 29, 2023

The State Administration for Market Regulation (SAMR) has imposed administrative penalties on Grand Pharmaceutical Group...

Company Drug

Ascentage Pharma to Present Clinical Results of Four Oncology Drugs at Medical Conference

Fineline Cube May 29, 2023

Suzhou-based Ascentage Pharma (HKG: 6855) has announced its intention to present the clinical results of...

Deals Policy / Regulatory

Hainan Province and NHSA Partner to Enhance Medical Insurance Industry with Real-World Data

Fineline Cube May 26, 2023

The government of Hainan province has entered into a strategic partnership with the National Healthcare...

Company Drug

BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting

Fineline Cube May 26, 2023

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at...

Policy / Regulatory

Shanghai Market Regulation Bureau Targets Unfair Competition in Pharmaceutical Sector

Fineline Cube May 26, 2023

The Shanghai market regulation bureau has released a document aimed at cracking down on unfair...

Company Deals

TianLong Science and Technology Expands into Northern Thailand with Hepatitis Diagnostics

Fineline Cube May 26, 2023

Xi’an-based med-tech firm TianLong Science and Technology Co., Ltd has reportedly entered into a supply...

Company Drug

Chia Tai Tianqing’s TQ-B3525 Heads for Priority Review for Recurrent Follicular Lymphoma

Fineline Cube May 26, 2023

The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQ-B3525, a...

Company Drug

Sanofi Launches Soliqua for Type 2 Diabetes Treatment in China

Fineline Cube May 26, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has announced the official market launch of Soliqua (insulin...

Company Drug

GenScript’s Legend Biotech Files Type II Variation Application for Carvykti with EMA

Fineline Cube May 26, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company Drug

Takeda and HutchMed’s Fruquintinib Receives Priority Review Status from FDA

Fineline Cube May 26, 2023

Takeda (TYO: 4502) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) have provided an update...

Policy / Regulatory

China’s NHC Releases Fourth List of Pediatric Priority Drugs to Boost Development

Fineline Cube May 26, 2023

The National Health Commission (NHC) of China has published its fourth list of pediatric drugs...

Posts pagination

1 … 512 513 514 … 657

Recent updates

  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
  • Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
  • Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg
  • AstraZeneca Secures FDA Approval for Subcutaneous Saphnelo in Systemic Lupus Erythematosus After Addressing Supplemental Data Request
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Company Drug

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Company Drug

Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.